SABS SAB Biotherapeutics, Inc.
Healthcare$3.81-2.31%ClosedMarket Cap: $36.4M
As of 2026-05-26
Valuation
P/E (TTM)
5.47
PEG
0.02
P/B
0.92
P/S
0.00
EV/EBITDA
13.12
DCF Value
$0.04
FCF Yield
-142.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.3%
ROA
-0.2%
ROIC
-24.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-20.0M | $-18.9M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-15.8M | $-16.9M | $— | — |
| FY null | $0.00 | -Infinity% | $-49.0M | $13.3M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-12.7M | $45.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-9.7M | $-10.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-10.8M | $-5.2M | $— | — |
| Q4 null | $114.7K | -585.0% | $-10.0M | $-11.4M | $— | — |
| FY null | $1.3M | -262.4% | $-42.9M | $-34.1M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-11.3M | $-10.3M | $— | — |
| Q2 null | $263.1K | -288.4% | $-10.2M | $-7.3M | $— | — |
| Q1 null | $944.6K | -110.1% | $-11.4M | $-5.0M | $— | — |
| Q4 2023 | $305.0K | -209.5% | $-18.9M | $-22.9M | $-3.86 | — |